Related Experiment Videos
[Use of converting enzyme inhibitors in children. I. General remarks]
1Kliniki Kardiologii Dzieciecej Slaskiej Akademii Medycznej, Katowicach.
Insights
Angiotensin-converting enzyme (ACE) inhibitors, like enalapril, show promise for treating pediatric circulatory issues and hypertension. However, careful dosing and consideration of contraindications are crucial, especially in newborns.
Area of Science:
- Pediatric Pharmacology
- Cardiovascular Therapeutics
Background:
- Limited research exists on ACE-inhibitor use in children.
- ACE-inhibitors, particularly enalapril, are being explored for pediatric cardiovascular conditions.
- Neonatal pharmacokinetics of these drugs differ, necessitating cautious administration.
Purpose of the Study:
- To review general information on ACE-inhibitor use in pediatric patients.
- To highlight contraindications and special considerations for ACE-inhibitor therapy in children.
- To assess the potential safety and efficacy of enalapril in pediatric circulatory insufficiency and hypertension.
Main Methods:
- Literature review of existing studies on ACE-inhibitors in childhood.
- Analysis of contraindications such as kidney artery stenosis, hypovolemia, and shock.
- Discussion of pharmacokinetic changes in early extrauterine life.
Main Results:
- ACE-inhibitors, including enalapril, have specific contraindications in children, even neonates.
- Drug kinetics are altered in newborns, requiring careful, low-dose initiation.
- Few studies currently document ACE-inhibitor use in pediatric populations.
Conclusions:
- Enalapril may be a relatively safe option for pediatric patients with circulatory insufficiency or arterial hypertension.
- Careful monitoring and dose adjustment are essential, particularly in neonates.
- Further research is needed to fully establish the role of ACE-inhibitors in pediatric cardiovascular care.
Abstract:
In the paper general remarks concerning ACE-inhibitors (especially enalapril) use in children have been described. Kidney artery stenosis, hypovolemia, and shock are only ones contraindications to this treatment in a childhood, even in the first period after birth. Anyhow, it was stressed on the basis of literature that at a beginning of extrauterine life the kinetics of these drugs is changed, thus they should be recommended carefully and in low doses. It was stressed, as well, that up to now appeared only a few papers concerning ACE-inhibitors use a childhood. It is suggested that enalapril can be used as an rather safety drug in pediatric patients suffering from circulatory insufficiency or arterial hypertension.